A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients

BACKGROUND AND OBJECTIVES Glioblastoma multiforme (GBM) is the most common and malignant type of primary brain tumors. Radiation therapy (RT) plus concomitant and adjuvant Temozolomide (TMZ) constitute standard treatment of GBM. Existing models for GBM growth do not consider the effect of different schedules on tumor growth and patient survival. However, clinical trials show that treatment schedule and drug dosage significantly affect patient survival. The goal is to provide a patient calibrated model for predicting survival according to the treatment schedule. METHODS We propose a top-down method based on artificial neural networks (ANN) and genetic algorithm (GA) to predict survival of GBM patients. A feed forward undercomplete Autoencoder network is integrated with the neuro-evolutionary (NE) algorithm in order to extract a compressed representation of input clinical data. The proposed NE algorithm uses GA to obtain optimal architecture of a multi-layer perceptron (MLP). Taguchi L16 orthogonal design of experiments is used to tune parameters of the proposed NE algorithm. Finally, the optimal MLP is used to predict survival of GBM patients. RESULTS Data from 8 related clinical trials have been collected and integrated to train the model. From 847 evaluable cases, 719 were used for train and validation and the remaining 128 cases were used to test the model. Mean absolute error of the predictions on the test data is 0.087 months which shows excellent performance of the proposed model in predicting survival of the patients. Also, the results show that the proposed NE algorithm is superior to other existing models in both the mean and variability of the prediction error.

[1]  J. Murray,et al.  Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy , 2002, British Journal of Cancer.

[2]  Le Zhang,et al.  Multi-scale, multi-resolution brain cancer modeling , 2008, Math. Comput. Simul..

[3]  Maciej Swat,et al.  Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. , 2015, Seminars in cancer biology.

[4]  Frank Thiele,et al.  Clinical Evaluation of a Multiparametric Deep Learning Model for Glioblastoma Segmentation Using Heterogeneous Magnetic Resonance Imaging Data From Clinical Routine , 2018, Investigative radiology.

[5]  Gustavo Marrero Callicó,et al.  Deep Learning-Based Framework for In Vivo Identification of Glioblastoma Tumor using Hyperspectral Images of Human Brain , 2019, Sensors.

[6]  Kristin R. Swanson,et al.  Toward Patient-Specific, Biologically Optimized Radiation Therapy Plans for the Treatment of Glioblastoma , 2013, PloS one.

[7]  Salvatore Torquato,et al.  Modeling the effects of vasculature evolution on early brain tumor growth. , 2006, Journal of theoretical biology.

[8]  Jennie W. Taylor,et al.  The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. , 2015, Neurosurgery.

[9]  Luigi Fortuna,et al.  M. L. P. Optimal Topology via Genetic Algorithms , 1993 .

[10]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[12]  H Paganetti,et al.  Methodologies in the modeling of combined chemo-radiation treatments , 2016, Physics in medicine and biology.

[13]  L. Deangelis,et al.  A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM) , 2007 .

[14]  Jeffrey Pennington,et al.  Semi-Supervised Recursive Autoencoders for Predicting Sentiment Distributions , 2011, EMNLP.

[15]  Max Kuhn,et al.  Applied Predictive Modeling , 2013 .

[16]  Blair Jarvis,et al.  Temozolomide A Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers , 2002 .

[17]  C. Davatzikos,et al.  Survival Analysis of Patients with High-Grade Gliomas Based on Data Mining of Imaging Variables , 2012, American Journal of Neuroradiology.

[18]  Katrina H. Smith,et al.  Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. , 2013, Neuro-oncology.

[19]  Peter T. Nelson,et al.  Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors , 2004, Clinical Cancer Research.

[20]  R. Sridhar,et al.  Cytotoxicity of glucose analogues in V79 multicell spheroids , 1979, In Vitro.

[21]  Xiaobo Zhou,et al.  Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis , 2012, BMC Bioinformatics.

[22]  Amy Loutfi,et al.  A review of unsupervised feature learning and deep learning for time-series modeling , 2014, Pattern Recognit. Lett..

[23]  D. Misailidou,et al.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Luke Macyszyn,et al.  Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. , 2016, Neuro-oncology.

[25]  M. M. Lotfi,et al.  A modified NSGA-II solution for a new multi-objective hub maximal covering problem under uncertain shipments , 2014 .

[26]  E. Kostelich,et al.  Virtual glioblastoma: growth, migration and treatment in a three‐dimensional mathematical model , 2009, Cell proliferation.

[27]  Ciprian Catana,et al.  Multimodality imaging and mathematical modelling of drug delivery to glioblastomas , 2016, Interface Focus.

[28]  J. Kirkwood,et al.  Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. , 2000, The oncologist.

[29]  Abbas Ahmadi,et al.  Simulation-based optimization of radiotherapy: Agent-based modeling and reinforcement learning , 2017, Math. Comput. Simul..

[30]  R. Stupp,et al.  The Role of Radio- and Chemotherapy in Glioblastoma , 2005, Oncology Research and Treatment.

[31]  Frederik Barkhof,et al.  Robust Deep Learning–based Segmentation of Glioblastoma on Routine Clinical MRI Scans Using Sparsified Training , 2020, Radiology. Artificial intelligence.

[32]  S. Baruchel,et al.  Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. , 2006, European journal of cancer.

[33]  R. Peck Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient. , 2018, Annual review of pharmacology and toxicology.

[34]  K. Aldape,et al.  Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.

[35]  R. Roy A Primer on the Taguchi Method , 1990 .

[36]  Mark R Gilbert,et al.  Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Vittorio Cristini,et al.  Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. , 2012, Journal of theoretical biology.

[38]  Davide Anguita,et al.  The 'K' in K-fold Cross Validation , 2012, ESANN.

[39]  Kalyanmoy Deb,et al.  A Comparative Analysis of Selection Schemes Used in Genetic Algorithms , 1990, FOGA.

[40]  A. Unterberg,et al.  Factors triggering an additional resection and determining residual tumor volume on intraoperative MRI: analysis from a prospective single-center registry of supratentorial gliomas. , 2016, Neurosurgical focus.

[41]  T van Doorn,et al.  Tumour resistance to cisplatin: a modelling approach , 2005, Physics in medicine and biology.

[42]  Haruna Chiroma,et al.  Neural networks optimization through genetic algorithm searches: A review , 2017 .

[43]  Dominique Barbolosi,et al.  Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model , 2001, Comput. Biol. Medicine.

[44]  Robert A Gatenby,et al.  A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.

[45]  Jafar Habibi,et al.  Hybrid multiscale modeling and prediction of cancer cell behavior , 2017, PloS one.

[46]  Josh Harguess,et al.  Generative NeuroEvolution for Deep Learning , 2013, ArXiv.

[47]  Norman F. Kirkby,et al.  A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. , 2010, Journal of theoretical biology.

[48]  Madjid Soltani,et al.  Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide , 2020, Comput. Methods Programs Biomed..

[49]  Trevor Hastie,et al.  An Introduction to Statistical Learning , 2013, Springer Texts in Statistics.

[50]  K. Aldape,et al.  Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. , 2015, Neuro-oncology.

[51]  Gargi Chakraborty,et al.  Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.

[52]  Susan M. Chang,et al.  Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. , 2014, Neuro-oncology.

[53]  Peter A. Wallace,et al.  A review on applications of genetic algorithm for artificial neural network , 2016 .

[54]  Robert J. Marks,et al.  Neural Smithing: Supervised Learning in Feedforward Artificial Neural Networks , 1999 .

[55]  P. Bossuyt,et al.  Individual patient data meta-analysis: a promising approach for evidence synthesis in reproductive medicine. , 2010, Human reproduction update.

[56]  Gael Varoquaux,et al.  Establishment of Best Practices for Evidence for Prediction: A Review. , 2019, JAMA psychiatry.

[57]  Jana L. Gevertz,et al.  Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation , 2011, Comput. Math. Methods Medicine.

[58]  Vittorio Cristini,et al.  Multiscale Modeling of Cancer: An Integrated Experimental and Mathematical Modeling Approach , 2010 .

[59]  M. Walker,et al.  An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.

[60]  B. Jeremic,et al.  Short-course Radiotherapy in Elderly and Frail Patients with Glioblastoma Multiforme. A Phase II Study , 1999, Journal of Neuro-Oncology.

[61]  Vittorio Maniezzo,et al.  Searching among Search Spaces: Hastening the genetic evolution of feedforward neural networks , 1993 .

[62]  Wei Cao,et al.  Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma , 2017, Scientific Reports.

[63]  Jimeng Sun,et al.  Constraint based temporal event sequence mining for Glioblastoma survival prediction , 2016, J. Biomed. Informatics.

[64]  Jason A. Chen,et al.  Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine , 2019, Front. Oncol..

[65]  Risto Miikkulainen,et al.  Designing neural networks through neuroevolution , 2019, Nat. Mach. Intell..

[66]  L. Schad,et al.  A generic support vector machine model for preoperative glioma survival associations. , 2015, Radiology.

[67]  Nikolaos K. Uzunoglu,et al.  A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide , 2006, IEEE Transactions on Biomedical Engineering.

[68]  Teresa B Ludermir,et al.  Global Optimization Methods for Designing and Training Feedforward Artificial Neural Networks , 2007 .

[69]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  John H. Holland,et al.  Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .

[71]  Yang Yang,et al.  Glioma Grading on Conventional MR Images: A Deep Learning Study With Transfer Learning , 2018, Front. Neurosci..

[72]  Genichi Taguchi,et al.  Taguchi's Quality Engineering Handbook , 2004 .

[73]  G Powathil,et al.  Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy , 2007, Physics in medicine and biology.

[74]  Neil G Burnet,et al.  A mathematical model of the treatment and survival of patients with high-grade brain tumours. , 2007, Journal of theoretical biology.

[75]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[76]  K. Camphausen,et al.  In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide , 2008, Clinical Cancer Research.

[77]  C. G. Newton,et al.  Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. , 1984, Journal of medicinal chemistry.

[78]  Gary H Lyman,et al.  The strengths and limitations of meta-analyses based on aggregate data , 2005, BMC Medical Research Methodology.

[79]  Nicolas André,et al.  Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.

[80]  L. Deangelis,et al.  Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. , 2013, Neuro-oncology.

[81]  Joseph D Butner,et al.  Simulating cancer growth with multiscale agent-based modeling. , 2015, Seminars in cancer biology.

[82]  Thomas G. Dietterich Adaptive computation and machine learning , 1998 .

[83]  J. Murray,et al.  Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.

[84]  G. Reifenberger,et al.  One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma , 2007 .

[85]  Gibin G Powathil,et al.  Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. , 2012, Journal of theoretical biology.

[86]  E S Newlands,et al.  Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.

[87]  Václav Snásel,et al.  Metaheuristic design of feedforward neural networks: A review of two decades of research , 2017, Eng. Appl. Artif. Intell..

[88]  D. Raabe,et al.  Hydrogen enhances strength and ductility of an equiatomic high-entropy alloy , 2017, Scientific Reports.

[89]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[90]  J. Knisely,et al.  Importance of hypoxia in the biology and treatment of brain tumors. , 2002, Neuroimaging clinics of North America.

[91]  Zhihui Wang,et al.  Cross-scale sensitivity analysis of a non-small cell lung cancer model: Linking molecular signaling properties to cellular behavior , 2007, Biosyst..

[92]  J M Wardlaw,et al.  Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[93]  Bowen Xin,et al.  Machine Learning Models for Multiparametric Glioma Grading With Quantitative Result Interpretations , 2019, Front. Neurosci..

[94]  S. Steinberg,et al.  National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. , 1994, International journal of radiation oncology, biology, physics.

[95]  M. Mrugala,et al.  Mechanisms of Disease: temozolomide and glioblastoma—look to the future , 2008, Nature Clinical Practice Oncology.

[96]  Jafar Habibi,et al.  Integrating evolutionary game theory into an agent-based model of ductal carcinoma in situ: Role of gap junctions in cancer progression , 2016, Comput. Methods Programs Biomed..

[97]  E. Hall,et al.  Radiobiology for the radiologist , 1973 .

[98]  Paul Kinahan,et al.  A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET , 2015, Journal of The Royal Society Interface.

[99]  Shuang Wu,et al.  Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas , 2019, Journal of Cancer Research and Clinical Oncology.